Predictors of Lorcaserin-Induced Weight Loss

• Status: Terminated
• Trial end date: 2020-02-14
• Target enrollment: 0
• Participant gender: All

Summary

This two-phase study aims to explore ways to predict who will respond well to the weight loss drug lorcaserin and to understand the mechanisms that develop which limit drug efficacy. Subjects will be recruited for a 5-week crossover study (phase 1) with lorcaserin and placebo followed by treatment with lorcaserin for 24 weeks (phase 2).

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Columbia University
• Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); New York State Psychiatric Institute

Criteria

Inclusion Criteria:

• Body Mass Index (BMI) 28-40

Exclusion Criteria:

• Any clinically significant or relevant medical condition, including:

• Diabetes

• Uncontrolled Hypertension

• Heart disease

• Bleeding disorder

• Kidney or liver dysfunction

• Neurologic disease

• Psychiatric or eating disorders

• Pregnancy or breastfeeding

• Use of tobacco or opiates

• History of alcohol or drug abuse

• Recent weight change +/- 5%

• Medications that affect body weight